Format

Send to

Choose Destination
See comment in PubMed Commons below
Breast Cancer (Auckl). 2011;5:209-26. doi: 10.4137/BCBCR.S6234. Epub 2011 Oct 9.

Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.

Author information

  • 1University of Miami, Leonard M. Miller School of Medicine, 1475 NW 12th Avenue, Suite 3310, Miami, Florida, USA.

Abstract

Exemestane is an irreversible inhibitor of the aromatase enzyme, which is a key component in the production of estrogen. The majority of breast cancers are sensitive to the proliferative effects of estrogen. Exemestane is approved for the adjuvant treatment of postmenopausal women with breast cancer after 2 to 3 years of tamoxifen therapy, based on a 32% improvement in disease-free survival compared with 5 years of tamoxifen alone (P < 0.001). Exemestane has also shown clinical benefits as an upfront therapy. The safety profile of exemestane shares some side effects with tamoxifen (hot flashes and arthralgia), but is not associated with an increased risk of endometrial cancer or thromboembolic events. This review will discuss in detail the efficacy and safety of exemestane in early breast cancer.

KEYWORDS:

aromatase inhibitor; breast cancer; disease-free survival; exemestane; tamoxifen

PMID:
22084574
PMCID:
PMC3201097
DOI:
10.4137/BCBCR.S6234
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Libertas Academica Icon for PubMed Central
    Loading ...
    Support Center